Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 11, 2011 - Issue 1
Submit an article Journal homepage
231
Views
11
CrossRef citations to date
0
Altmetric
Special Report

JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia

Fatih M Uckun Division of Hematology–Oncology, Department of Pediatrics, Children’s Center for Cancer and Blood Diseases, University of Southern California, Keck School of Medicine, Los Angeles, CA 90027-0367, USA. [email protected]; Developmental Therapeutics Program, Institute for Pediatric Clinical Research, Children’s Hospital Los Angeles MS#57, Los Angeles, CA 90027-0367, USA; Division of Hematology–Oncology, Department of Pediatrics, Children’s Center for Cancer and Blood Diseases, University of Southern California, Keck School of Medicine, Los Angeles, CA 90027-0367, USA. [email protected]; Developmental Therapeutics Program, Institute for Pediatric Clinical Research, Children’s Hospital Los Angeles MS#57, Los Angeles, CA 90027-0367, USA
,
Jason Pitt Gene Silencing Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA; Gene Silencing Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
&
Sanjive Qazi Department of Biology and Bioinformatics Program, Gustavus Adolphus College, 800 W College Avenue, St Peter, MN 56082, USA; Department of Biology and Bioinformatics Program, Gustavus Adolphus College, 800 W College Avenue, St Peter, MN 56082, USA
Pages 37-48 | Published online: 10 Jan 2014

References

  • Miosge LA, Goodnow CC. Genes, pathways and checkpoints in lymphocyte development and homeostasis. Immunol. Cell Biol.83, 318–335 (2005).
  • Tortolani PJ, Lal BK, Riva A et al. Regulation of JAK3 expression and activation in human B cells and B cell malignancies. J. Immunol.155, 5220–5226 (1995).
  • Sharfe N, Dadi HK, O’Shea JJ, Roifman CM. JAK3 activation in human lymphocyte precursor cells. Clin. Exp. Immunol.108, 552–556 (1997).
  • Sudbeck EA, Liu X-P, Narla RK et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin. Cancer Res.5, 1569–1582 (1999).
  • Scharfe N, Dadi HK, Roifman CM. JAK3 protein tyrosine kinase mediates interleukin-7 induced activation of phosphatidylinositol-3 kinase. Blood86, 2077–2085 (1995).
  • Malin S, McManus S, Cobaleda C et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat. Immunol.11, 171–179 (2010).
  • Lin Q, Lai R, Chirieac LR et al. Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines. Am. J. Pathol.167, 969–980 (2005).
  • Cornejo MG, Boggon TJ, Mercher T. JAK3: a two-faced player in hematologic disorders. Int. J. Biochem. Cell Biol.41, 2376–2379 (2009).
  • Kawahara A, Minami Y, Miyazaki T, Ihle JN, Taniguchi T. Critical role of the interleukin 2 (IL-2) receptor γ-chain associated JAK3 in the IL-2 induced c-fos and c-myc, but not bcl-1 gene induction. Proc. Natl Acad. Sci. USA92, 8724–8728 (1995).
  • Walker SR, Nelson EA, Frank DA. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas. Oncogene26, 224–233 (2007).
  • Duy C, Yu JJ, Nahar R et al. BCL6 is critical for the development of a diverse B cell repertoire. J. Exp. Med.207, 1209–1221 (2009).
  • Han S-S, Yun H, Son D-J et al. NF-κB/STAT3/PI3K signaling crosstalk in iMycEµ B lymphoma. Mol. Cancer9, 97 (2010).
  • Juarez J, Baraz R, Gaundar S, Bradstock K, Bendall L. Interaction of interleukin-7 and interleukin-3 with the CXCL12-induced proliferation of B-cell progenitor acute lymphoblastic leukemia. Haematologica92, 450–459 (2007).
  • Juarez J, Thien M, Dela Pena A, Baraz R, Bradstock KF, Bendall LJ. CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukemia cells to the bone marrow via activation of p38MAPK. Br. J. Haematol.145, 491–499 (2009).
  • Vila-Coro AJ, Rodriguez-Frade JM, DeAna AM, Moreno-Ortiz MC, Martinez C, Mellado M. The chemokine SDF-1 triggers CXCR4 receptor dimerization and activates the JAK–STAT pathway. FASEB J.13, 1699–1710 (1999).
  • Wang L, Fortney JE, Gibson LF. Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. Leuk. Res.28, 733–742 (2004).
  • Hornakova T, Staerk J, Royer Y et al. Acute lymphoblastic leukemia-associated JAK1 mutants activate the Janus kinase/STAT pathway via interleukin 9 receptor a homodimers. J. Biol. Chem.284, 6773–6781 (2009).
  • Lu X, Huang LJ, Lodish HF. Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J. Biol. Chem.283, 5258–5266 (2008).
  • Malka Y, Hornakova T, Royer Y et al. Ligand-independent homomeric and heteromeric complexes between interleukin-2 or -9 receptor subunits and the γ chain. J. Biol. Chem.283, 33569–33577 (2008).
  • Qazi S, Uckun FM. Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets. Br. J. Haematol.149(6), 865–873 (2010).
  • Mulligan CG, Zhang J, Harvey RC et al.JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl Acad. Sci. USA106, 9414–9418 (2009).
  • Uckun FM, Goodman P, Ma H, Dibirdik I, Qazi S. CD22 exon 12 deletion as a novel pathogenic mechanism of human B-precursor leukemia. Proc. Natl Acad. Sci. USA107, 16852–16857 (2010).
  • Irizarry RA, Hobbs B, Collin F et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics4(2), 249–264 (2003).
  • Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics19(2), 185–193 (2003).
  • Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol.3(1), Article 3 (2004).
  • Wettenhall JM, Simpson KM, Satterley K, Smyth GK. affylmGUI: a graphical user interface for linear modeling of single channel microarray data. Bioinformatics22(7), 897–899 (2006).
  • Takeshita T, Arita T, Higuchi M et al. STAM, signal transducing adaptor molecule, is associated with Janus kinases and involved in signaling for cell growth and c-myc induction. Immunity6, 449–457 (1997).
  • Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T-cells by γ(c) family cytokines. Nat. Rev. Immunol.9, 480–490 (2009).
  • Walters DK, Mercher T, Gu TL et al. Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell10, 65–75 (2006).
  • Sato T, Toki T, Kanezaki R et al. Functional analysis of JAK3 mutations in transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Br. J. Hematol.141, 681–688 (2008).
  • Malinge S, Ragu C, Della-Valle V et al. Activating mutations in human acute megakaryoblastic leukemia. Blood112, 4220–4226 (2008).
  • Cornejo MG, Kharas MG, Werneck MB et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood113, 2746–2754(2009).
  • Yamashita Y, Yuan J, Suetake I et al. Array-based genomic resequencing of human leukemia. Oncogene29, 3723–3731 (2010).
  • Qiu L, Lai R, Lin Q et al. Autocrine release of interleukin-9 promotes JAK3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood108, 2407–2415 (2006).
  • Bard JD, Gelebart P, Anand M et al. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am. J. Pathol.175, 825–834 (2009).
  • Amin HM, Medeiros LJ, Ma Y et al. Inhibition of JAK3 induces apoptosis and decreases anaplastic lymphoma kinase activity in anaplastic large cell lymphoma. Oncogene22, 5399–5407 (2003).
  • Steele AJ, Prentice AG, Cwynarski K et al. The JAK3 selective inhibitor PF-956980 reverses resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment. Blood DOI: 10.1182/blood-2009-2009-245811 (2010) (Epub ahead of print).
  • Martinez-Lostao L, Briones J, Forne I et al. Role of STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. Leukemia46, 435–442 (2005).
  • Han Y, Amin HM, Franko B, Frantz C, Shi X, Lai R. Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM–ALK in ALK+ anaplastic large-cell lymphoma. Blood108, 2796–2803 (2006).
  • Piessevaux J, Lavens D, Peelman F, Tavernier J. The many faces of the SOCS box. Cytokine Growth Factor Rev.19, 371–381 (2008).
  • Endo TA, Masuhara M, Yokouchi M et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature387, 921–924 (1997).
  • Jumaa H, Bossaller L, Portugal K et al. Deficiency of the adaptor SLP-65 in pre-B cell acute lymphoblastic leukemia. Nature423, 452–456 (2003).
  • Duy C, Sprangers M, Klemm L et al. Inactivation of pre-B cell receptor-mediated tumor suppression by aberrant splicing in Ph+ acute lymphoblastic leukemia. Blood (ASH Annual Meeting Abstracts)114 (2009) (Abstract 579).
  • Nakayama J, Yamamoto M, Hayashi K et al. BLNK suppresses pre-B cell leukemogenesis through inhibition of JAK3. Blood113, 1483–1492 (2009).
  • Uckun FM, Dibirdik I, Smith R et al. Interleukin 7 receptor ligation stimulates tyrosine phosphorylation, inositol phospholipid turnover, and clonal proliferation of human B-cell precursors. Proc. Natl Acad. Sci. USA88(9), 3589–3593 (1991).
  • Morrissey PJ, Conlon P, Charrier K et al. Administration of IL-7 to normal mice stimulates B-lymphopoiesis and peripheral lymphadenopathy. J. Immunol.147, 561–568 (1991).
  • Fisher AG, Burdet C, Bunce C et al. Lymphoproliferative disorders in IL-7 transgenic mice: expansion of immature B-cells which retain macrophage potential. Int. Immunol.7, 415–423 (1995).
  • Mertshing E, Grawunder U, Meyer V et al. Phenotypic and functional analysis of B-lymphopoiesis in interleukin-7 transgenic mice: expansion of pro-B/pre-B cell number and persistence of B lymphocyte development in lymph nodes and spleen. Eur. J. Immunol.26, 28–33 (1996).
  • Rich BE, Campos-Torres J, Tepper RI, Moradith FW, Leder P. Cutaneous lymphoproliferation and lymphomas in interleukin 7 transgenic mice. J. Exp. Med.177, 305–316 (1993).
  • Touw I, Pouweis K, van Agthoven T et al. Interleukin 7 is a growth factor of precursor B and T acute lymphoblastic leukemia. Blood75, 2097–2101 (1990).
  • Henney CS. Interleukin 7: effects on early events in lymphopoiesis. Immunol. Today10, 170–173 (1989).
  • Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC. JAK kinases overexpression promotes in vitro cell transformation. Oncogene27, 1511–1519 (2008).
  • Bonetta L. Leukemia case triggers tighter gene therapy controls. Nat. Med.8, 1189 (2002).
  • Witthuhn BA, Williams MD, Kerawalla H, Uckun FM. Differential substrate recgnition capabilities of Janus protein tyrosine kinases within the interleukin 2 receptor system: JAK3 as a potential molecular target for treatment of leukemias with a hyperactive JAK–STAT signaling machinery. Leuk. Lymphoma32, 289–297 (1999).
  • Zhu MH, Berry JA, Russell SM, Leonard WJ. Delineation of the regions of interleukin 2 (IL-2) receptor β chain important for association of JAK1 and JAK3. J. Biol. Chem.273, 10719–10725 (1998).
  • Fujii H. Receptor expression is essential for proliferation induced by dimerized JAK kinases. Biochem. Biophys. Res. Commun.370, 557–560 (2008).
  • James C, Ugo V, Le Couedic JP et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature434, 1144–1148 (2005).
  • Kralovics R, Passamonti F, Buser AS et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med.352, 1779–1790 (2005).
  • Jeong EG, Kim MS, Nam HK et al. Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin. Cancer Res.14, 3716–3722 (2008).
  • Thompson JE, Cubbon RM, Cummings RT et al. Photochemical preparation of a pyridone containing tetracycle: a JAK protein kinase inhibitor. Bioorg. Med. Chem. Lett.12, 1219–1223 (2002).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.